_______________________________________________________________________________________________________________
After doubling the business in 2025, Abingdon is poised to achieve a similar outcome in 2026 by leveraging the same solid growth strategy. Chris elaborates on the key components of this strategy:“ There are three main pillars to our approach. First, we are focused on being knowledge leaders in lateral flow testing and in-vitro diagnostics in general. We have a highly experienced team that have been through the process of developing, scaling, manufacturing and commercializing assays many times, allowing us to apply that expertise effectively. Second, our comprehensive service proposition provides all the necessary components for customers to move from concept to commercial success. In other words, we are a one-stop shop, which gives us the ability to synchronize various workstreams, resulting in improved efficiency and cost-effectiveness for our clients. Finally, our optionality on manufacturing is essential in today’ s environment of tariffs. We offer customers the ability and choice to manufacture in the UK, the US, or in both countries if required, providing a lot of flexibility as they plan their own commercial strategies moving forward,” he states.
Expanding in the US has contributed positively to Abingdon’ s growth plans, enabling the company to reach more customers without the burden of tariffs.“ Since establishing our US facility in April 2025, the commercial side of the business has been thriving. Within that period, we have secured a number of customers across the US, ranging from prestigious American universities, to start-up companies through to large blue-chip organizations. Additionally, we are actively working on over six contracts within the US and continue to see a great level of interest from prospective clients. Overall, our expansion in the US has gone extremely well,” Chris informs.
“ We have gone from strength to strength since our opening in April, seeing a huge
170